Top

BMC Pediatrics

Published in:

Open Access 01-12-2023 | Milrinone | Research

Milrinone for the treatment of heart failure caused by severe Pneumonia in children with congenital heart disease: a meta-analysis

Authors: Wenshen Shao, Shuangshuang Diao, Lu Zhou, Lina Cai

Published in: BMC Pediatrics | Issue 1/2023

Abstract

Background

Children with congenital heart disease (CHD) are easily complicated by severe pneumonia and heart failure. We aimed to conduct a meta-analysis to evaluate the effects and safety of milrinone for the treatment of heart failure caused by severe pneumonia in children with CHD to provide evidence for the clinical CHD treatment.

Methods

Two authors searched MEDLINE, PubMed, Embase, Science Direct, Cochrane Central Register of Controlled Trials, the Cochrane Library, Wanfang database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure (CNKI) for randomized controlled trials (RCTs) about the application of milrinone in the treatment of heart failure caused by severe pneumonia in children with CHD in children up to December 10, 2022. Two evaluators independently selected the literature, extracted data and evaluated the methodological quality, meta-analysis was carried out with RevMan 5.3 software.

Results

Eight RCTs involving 680 CHD children complicated by severe pneumonia and heart failure were included in this meta-analysis. Meta-analysis indicated that total effective rate of the milrinone group was higher than that of control group (RR = 1.25, 95%CI: 1.17 ~ 1.34, P < 0.001), the time to stable heart rate of the milrinone group was less than that of control group (RR=-0.88, 95%CI: -1.09~ -0.67, P < 0.001). The time to stable respiration of the milrinone group was less than that of control group (RR=-0.98, 95%CI: -1.17~ -0.78, P < 0.001). The LVEF of the milrinone group was higher than that of control group (RR = 6.46, 95%CI: 5.30 ~ 7.62, P < 0.001). There was no significant difference in the incidence of adverse reactions between the milrinone group and control group (RR = 0.85, 95%CI: 0.47 ~ 1.56, P = 0.061). Funnel plots and Egger regression test results indicated that there were no statistical publication bias amongst the synthesized outcomes (all P > 0.05).

Conclusions

Milrinone is beneficial to improve clinical symptoms and cardiac function and increase the therapeutic effect and safety in children with CHD complicated by severe pneumonia and heart failure. However, more RCTs with large samples and rigorous design are needed to verify this finding.

Taylor RS, Dalal HM, McDonagh STJ. The role of cardiac rehabilitation in improving cardiovascular outcomes. Nat Rev Cardiol. 2022;19(3):180–94. https://doi.org/10.1038/s41569-021-00611-7.CrossRefPubMed

Soleimani A, Soleimani Z. Presentation and outcome of congenital Heart Disease during Covid-19 pandemic: a review. Curr Probl Cardiol. 2022;47(1):100905. https://doi.org/10.1016/j.cpcardiol.2021.100905.CrossRefPubMed

Jat NK, Bhagwani DK, Bhutani N, Sharma U, Sharma R, Gupta R. Assessment of the prevalence of congenital Heart Disease in children with Pneumonia in tertiary care hospital: a cross-sectional study. Ann Med Surg (Lond). 2022;73:103111. https://doi.org/10.1016/j.amsu.2021.103111.CrossRefPubMed

Sadoh WE, Osarogiagbon WO. Underlying congenital Heart Disease in Nigerian children with Pneumonia. Afr Health Sci. 2013;13(3):607–12. https://doi.org/10.4314/ahs.v13i3.13.CrossRefPubMedPubMedCentral

Kishore S, Kumar M, Kumar A, Gupta A, Chandan C, Anshuman A, Prakash J, Sinha S, Kumar N. Clinical and Echocardiographic Profile of Congenital Heart Diseases in the 0-12-Year Age Group in a Tertiary Care Medical Institute in Eastern India: a Retrospective, cross-sectional study. Cureus. 2022;14(6):e26114. https://doi.org/10.7759/cureus.26114.CrossRefPubMedPubMedCentral

Gist KM, Korst A, Nakano SJ, Stauffer BL, Karimpour-Fard A, Zhou W, Campbell K, Wempe MF, Sucharov CC, Miyamoto SD. Circulating cyclic adenosine monophosphate concentrations in milrinone treated paediatric patients after congenital heart Surgery. Cardiol Young. 2021;31(9):1393–400. https://doi.org/10.1017/S1047951121000251.CrossRefPubMedPubMedCentral

Korkmaz L, Ozdemir A, Pamukcu O, Gunes T, Ozturk MA. Which Inotropic Drug, Dobutamine or Milrinone, is clinically more effective in the treatment of Postligation Cardiac Syndrome in Preterm infants? Am J Perinatol. 2022;39(2):204–15. https://doi.org/10.1055/s-0040-1715118.CrossRefPubMed

Ahmed H, VanderPluym C. Medical management of pediatric Heart Failure. Cardiovasc Diagn Ther. 2021;11(1):323–35. https://doi.org/10.21037/cdt-20-358.CrossRefPubMedPubMedCentral

Harris KC, Mackie AS, Dallaire F, Khoury M, Singer J, Mahle WT, Klassen TP, McCrindle BW. Unique challenges of Randomised controlled trials in Pediatric Cardiology. Can J Cardiol. 2021;37(9):1394–403. https://doi.org/10.1016/j.cjca.2021.06.013.CrossRefPubMed

10.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178–89. https://doi.org/10.1136/bmj.n71.CrossRefPubMed

11.

Chen T, Li Y. Efficacy of milrinone in children with congenital Heart Disease complicated by severe Pneumonia and Heart Failure. J Chin Western Med. 2015;3(29):17–8. DOI: CNKI:SUN:ZXJH.0.2015-29-011.

12.

Huang H. Clinical observation of milrinone in treatment of children with congenital Heart Disease complicated by severe Pneumonia and Heart Failure. J Chin Practical Med. 2017;12(36):94–7. https://doi.org/10.14163/j.cnki.11-5547/r.2017.36.053.CrossRef

13.

Lin H, Li Y, Xiao S. Clinical analysis of milrinone in the treatment of congenital Heart Disease complicated by acute Heart Failure in children. J Mod Med Health. 2021;37(16):3–5. https://doi.org/10.3969/j.issn.1009-5519.2021.16.023.CrossRef

14.

Ma R. Evaluation of milrinone in children with congenital Heart Disease complicated by severe Pneumonia and Heart Failure. J Chin Continuing Med Educ. 2020;12(11):3–5. DOI: CNKI:SUN:JXUY.0.2020-11-058.

15.

Tang J. Clinical analysis of milrinone in the treatment of infantile congenital Heart Disease complicated by severe Pneumonia and Heart Failure. Contemp Med. 2018;24(17):14–7. https://doi.org/10.3969/j.issn.1009-4393.2018.017.005.CrossRef

16.

Wang X, Liu J, Zou Y. Clinical effect of milrinone in the treatment of congenital Heart Disease complicated by severe Pneumonia and Heart Failure in children. J Chin Contemp Med. 2020;27(4):107–9. DOI: CNKI:SUN:ZGUD.0.2020-04-030.

17.

Wu C, Zhong X, Zhong F. Clinical efficacy of milrinone in the treatment of congenital Heart Disease complicated by Heart Failure. J Drug Evaluation. 2016;13(13):61–4. https://doi.org/10.12010/j.issn.1673-5846.2016.05.038.CrossRef

18.

Wu Y. Analysis of the efficacy of milrinone in children with congenital Heart Disease Pneumonia complicated by Heart Failure. Heilongjiang Med. 2017;30(3):558–9. https://doi.org/10.14035/j.cnki.hljyy.2017.03.035.CrossRef

19.

Ehwerhemuepha L, Roth B, Patel AK, Heutlinger O, Heffernan C, Arrieta AC, Sanger T, Cooper DM, Shahbaba B, Chang AC, et al. Association of Congenital and Acquired Cardiovascular conditions with COVID-19 Severity among Pediatric patients in the US. JAMA Netw Open. 2022;5(5):e2211967. https://doi.org/10.1001/jamanetworkopen.2022.11967.CrossRefPubMedPubMedCentral

20.

Rohit M, Rajan P. Approach to cyanotic congenital Heart Disease in children. Indian J Pediatr. 2020;87(5):372–80. https://doi.org/10.1007/s12098-020-03274-3.CrossRefPubMed

21.

van der Bom T, Zomer AC, Zwinderman AH, Meijboom FJ, Bouma BJ, Mulder BJ. The changing epidemiology of congenital Heart Disease. Nat Rev Cardiol. 2011;8(1):50–60. https://doi.org/10.1038/nrcardio.2010.166.CrossRefPubMed

22.

Hinton RB, Ware SM. Heart Failure in Pediatric patients with congenital Heart Disease. Circ Res. 2017;120(6):978–94. https://doi.org/10.1161/CIRCRESAHA.116.308996.CrossRefPubMedPubMedCentral

23.

Toganel R, Benedek I, Suteu C, Blesneac C. Management of pulmonary arterial Hypertension associated with congenital Heart Disease. Rom J Intern Med. 2007;45(3):229–34.PubMed

24.

Picchio FM, Formigari R, Balducci A. Pediatric Heart Failure. Minerva Cardioangiol. 2008;56(3):311–9.PubMed

25.

Storstein L. Clinical and circulatory aspects of digitalis in Heart Failure. Eur Heart J. 1982;3(Suppl D):59–64.PubMed

26.

Vyas A, Bachani N, Thakur H, Lokhandwala Y. Digitalis toxicity: ECG vignette. Indian Heart J. 2016;68(Suppl 2):223–S225. https://doi.org/10.1016/j.ihj.2016.03.032.CrossRef

27.

Jothinath K, Balakrishnan S, Raju V, Menon S, Osborn J. Clinical efficacy of levosimendan vs milrinone in preventing low cardiac output syndrome following pediatric cardiac Surgery. Ann Card Anaesth. 2021;24(2):217–23. https://doi.org/10.4103/aca.ACA_160_19.CrossRefPubMedPubMedCentral

28.

Kanazawa T, Shimizu K, Iwasaki T, Baba K, Otsuki S, Kotani Y, Kasahara S, Morimatsu H. Perioperative Milrinone infusion improves one-year Survival after the Norwood-Sano Procedure. J Cardiothorac Vasc Anesth. 2021;35(7):2073–8. https://doi.org/10.1053/j.jvca.2021.02.017.CrossRefPubMed

29.

Vogel DJ, Brame A, Hanks F, Remmington C, Chung N, Camporota L. Improved oxygenation with inhaled milrinone in mechanically ventilated patients with severe COVID-19. Br J Anaesth. 2021;127(3):e111–3. https://doi.org/10.1016/j.bja.2021.06.002.CrossRefPubMed

30.

Rahiman S, Kowalski R, Kwok SY, Matha S, Jones B, Smolich JJ, Mynard JP, Butt W, Millar J. Milrinone acts as a Vasodilator but not an inotrope in children after cardiac surgery-insights from Wave Intensity Analysis. Crit Care Med. 2020;48(11):e1071–8. https://doi.org/10.1097/CCM.0000000000004622.CrossRefPubMed

31.

Thorlacius EM, Suominen PK, Wahlander H, Keski-Nisula J, Vistnes M, Ricksten SE, Synnergren M, Romlin BS, Castellheim A. The Effect of Levosimendan Versus Milrinone on the occurrence rate of Acute kidney Injury following congenital heart Surgery in infants: a Randomized Clinical Trial. Pediatr Crit Care Med. 2019;20(10):947–56. https://doi.org/10.1097/PCC.0000000000002017.CrossRefPubMed

32.

Hallik M, Ilmoja ML, Tasa T, Standing JF, Takkis K, Veigure R, Kipper K, Jalas T, Raidmae M, Uibo K, et al. Population Pharmacokinetics and Dosing of Milrinone after Patent Ductus Arteriosus Ligation in Preterm infants. Pediatr Crit Care Med. 2019;20(7):621–9. https://doi.org/10.1097/PCC.0000000000001879.CrossRefPubMed

33.

Cavigelli-Brunner A, Hug MI, Dave H, Baenziger O, Buerki C, Bettex D, Cannizzaro V, Balmer C. Prevention of Low Cardiac output Syndrome after Pediatric Cardiac Surgery: a double-blind Randomized Clinical Pilot Study comparing Dobutamine and Milrinone. Pediatr Crit Care Med. 2018;19(7):619–25. https://doi.org/10.1097/PCC.0000000000001533.CrossRefPubMed

34.

Lannon M, Martyniuk A, Sharma S. Intravenous milrinone for delayed cerebral ischaemia in aneurysmal Subarachnoid Haemorrhage: a systematic review. Br J Neurosurg. 2022;1–6. https://doi.org/10.1080/02688697.2022.2125160.

35.

Loomba RS, Dorsey V, Villarreal EG, Flores S. The effect of milrinone on hemodynamic and gas exchange parameters in children. Cardiol Young. 2020;30(1):55–61. https://doi.org/10.1017/S1047951119002865.CrossRefPubMed

36.

Beshish AG, Aljiffry A, Aronoff E, Chauhan D, Zinyandu T, Basu M, Shashidharan S, Maher KO. Milrinone for treatment of elevated lactate in the pre-operative newborn with hypoplastic left heart syndrome. Cardiol Young. 2022;1–9. https://doi.org/10.1017/S1047951122003171.

37.

Hollander SA, Wujcik K, Schmidt J, Liu E, Lin A, Dykes J, Good J, Brown M, Rosenthal D. Home Milrinone in Pediatric Hospice Care of Children with Heart Failure. J Pain Symptom Manage. 2022. https://doi.org/10.1016/j.jpainsymman.2022.11.014.CrossRefPubMed

38.

Eagles ME, MacLean MA, Kameda-Smith MM, Duda T, Persad ARL, Almojuela A, Bokhari R, Iorio-Morin C, Elkaim LM, Rizzuto MA, et al. Subarachnoid Hemorrhage, delayed cerebral ischemia, and Milrinone Use in Canada. Can J Neurol Sci. 2022;1:1–9. https://doi.org/10.1017/cjn.2022.44.CrossRef

39.

Ziff OJ, Kotecha D. Digoxin: the good and the bad. Trends Cardiovasc Med. 2016;26(7):585–95. https://doi.org/10.1016/j.tcm.2016.03.011.CrossRefPubMed

40.

Konstantinou DM, Karvounis H, Giannakoulas G. Digoxin in Heart Failure with a reduced ejection fraction: a risk factor or a risk marker. Cardiology. 2016;134(3):311–9. https://doi.org/10.1159/000444078.CrossRefPubMed

41.

Kenneally AM, Agbana P, Gardner B, Bae Y, Mitchell T, Beckman EJ. Compatibility of calcium chloride with milrinone, epinephrine, vasopressin, and heparin via in vitro testing and simulated Y-site administration. Am J Health Syst Pharm. 2022. https://doi.org/10.1093/ajhp/zxac306.CrossRef

42.

McPherson A, Nguyen C, Groninger H, Anderson KM, Henderson P, Rao A. Continuous intravenous inotropic support for Advanced Heart Failure: palliative considerations. J Pain Palliat Care Pharmacother. 2022;36(1):59–67. https://doi.org/10.1080/15360288.2022.2050456.CrossRefPubMed

43.

Castle-Kirszbaum M, Lai L, Maingard J, Asadi H, Danks RA, Goldschlager T, Chandra RV. Intravenous milrinone for treatment of delayed cerebral ischaemia following Subarachnoid Haemorrhage: a pooled systematic review. Neurosurg Rev. 2021;44(6):3107–24. https://doi.org/10.1007/s10143-021-01509-1.CrossRefPubMed

44.

Santos-Teles AG, Ramalho C, Ramos JGR, Passos RDH, Gobatto A, Farias S, Batista PBP, Caldas JR. Efficacy and safety of milrinone in the treatment of cerebral vasospasm after subarachnoid Hemorrhage: a systematic review. Rev Bras Ter Intensiva. 2020;32(4):592–602. https://doi.org/10.5935/0103-507X.20200097.CrossRefPubMedPubMedCentral

45.

Qasim A, Jain SK. Milrinone Use in Persistent Pulmonary Hypertension of the Newborn. Neoreviews. 2020;21(3):e165–78. https://doi.org/10.1542/neo.21-3-e165.CrossRefPubMed

46.

Ren YS, Li LF, Peng T, Tan YJ, Sun Y, Cheng GL, Zhang GM, Li J. The effect of milrinone on mortality in adult patients who underwent CABG Surgery: a systematic review of randomized clinical trials with a meta-analysis and trial sequential analysis. BMC Cardiovasc Disord. 2020;20(1):328. https://doi.org/10.1186/s12872-020-01598-8.CrossRefPubMedPubMedCentral

Title: Milrinone for the treatment of heart failure caused by severe Pneumonia in children with congenital heart disease: a meta-analysis
Authors: Wenshen Shao
Shuangshuang Diao
Lu Zhou
Lina Cai
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Milrinone
Heart Failure
Pneumonia
Published in: BMC Pediatrics / Issue 1/2023
Electronic ISSN: 1471-2431
DOI: https://doi.org/10.1186/s12887-023-04360-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Milrinone for the treatment of heart failure caused by severe Pneumonia in children with congenital heart disease: a meta-analysis

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Posterior urethral valve in thai boys

White-Sutton syndrome and congenital heart disease: case report and literature review

Improved access to HIV diagnosis and linkage to antiretroviral therapy among children in Southern Nigeria: a before-after study

Correction: The relative age effect on fundamental movement skills in Chinese children aged 3–5 years

Air-leak syndrome in a premature newborn

Genetic studies in the Pakistani population reveal novel associations with ventricular septal defects (VSDs)